Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.

SecurityRICE / Rice Energy Inc. (762760106)
IndustryCrude Petroleum and Natural Gas
Institutional Owners12
Institutional Shares5,757,662 - 2.52%
Common Shares Outstanding228,033,281 shares (as of 2017-09-30)
Institutional Value$ 123,783,000 USD

Institutional Stock Ownership and Shareholders()

Rice Energy Inc. (NYSE:RICE) has 12 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 5,757,662 shares. Largest shareholders include BlackRock Institutional Trust Company, N.A., BlackRock Fund Advisors, EverPoint Asset Management, LLC, Steadfast Advisors Lp, Janus Capital Management Llc, BlackRock Group LTD, Century Capital Management, LLC, BlackRock Advisors LLC, BlackRock Investment Management, LLC, and Spot Trading L.L.C.
Rice Energy Inc. (NYSE:RICE) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev
Prev Value
Current Value
2017-07-27 13F-HR Spot Trading L.l.c. Call 22,100 589
2017-05-01 13F-HR Spot Trading L.L.C 0 4,141 0 98
2017-05-15 13F-HR R&F Capital Advisors LP 11,590 0 -100.00 247 0
2017-02-10 13F-HR BlackRock Group LTD 117,522 181,417 54.37 3,069 3,873 26.20
2018-05-15 13F-HR Ancora Advisors, LLC 600,000 0 -100.00 17,650 0 -100.00
2017-05-01 13F-HR Spot Trading L.L.C Put 43,600 1,033
2017-08-10 13F-HR Century Capital Management, LLC 50,872 73,489 44.46 1,206 1,957 62.27
2017-02-10 13F-HR BlackRock Advisors LLC 67,071 1,432
2017-08-08 13F-HR Airain ltd 22,225 0 -100.00 527 0 -100.00
2018-02-14 13F-HR TPH Asset Management, LLC 67,728 0 -100.00 1,960 0 -100.00
2018-02-02 13F-HR Texan Capital Management 53,480 0 -100.00 1,548 0 -100.00
2017-02-14 13F-HR STEADFAST ADVISORS LP 175,096 259,258 48.07 4,572 5,535 21.06
2017-02-07 13F-HR FIRST NEW YORK SECURITIES LLC /NY 10,000 0 -100.00 261,100 0 -100.00
2017-02-14 13F-HR EverPoint Asset Management, LLC 0 300,000 0.00 0 6,405
2017-02-10 13F-HR BlackRock Institutional Trust Company, N.A. 108,481 3,149,746 2,803.50 2,832 67,247 2,274.54
2017-01-13 13F-HR MetLife Securities, Inc 111 111 0.00 3 2 -33.33
2017-05-01 13F-HR Spot Trading L.L.C Call 9,100 216
2018-02-14 13F-HR GLG Partners LP 793,855 0 -100.00 22,974 0 -100.00
2017-07-27 13F-HR Spot Trading L.l.c. Put 15,900 423
2017-05-16 13F-HR JANUS CAPITAL MANAGEMENT LLC 302,700 195,789 -35.32 6,463 4,640 -28.21
2017-02-10 13F-HR BlackRock Fund Advisors 147,509 1,464,719 892.97 3,851 31,272 712.05
2017-02-10 13F-HR BlackRock Investment Management, LLC 21 61,921 294,761.90 1 1,322 132,100.00
2017-01-03 13F-HR Vollero Beach Capital Partners LLC 153,781 0 -100.00 3,389 0 -100.00

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

EQT Gears Up for Huron Play Acres' Divestment to Reduce Debt

2018-06-29 zacks
EQT Corporation (EQT - Free Report) recently agreed to divest around 2.5 million non-core Huron Play acres for $575 million, to Diversified Gas and Oil Plc. The net acres are located in Southern Appalachia. The transaction is expected to conclude in July 2018. (21-0)

4 Reasons These High-Yield, Hyper Growth Income Stocks Could Make You Rich

2018-06-25 seekingalpha
Thanks to a perfect storm of negative (but temporary) factors, MLPs have spent almost four years in a bear market. (21-0)

EQT Midstream Partners: To Wait Or Not To Wait

2018-06-18 seekingalpha
My investment club will have its shares of Rice Midstream converted to EQT Midstream in the third quarter of 2018. (8-0)

Rice Midstream Partners: The EQM Merger Pushes Breakeven Into 2019 For Long-Term Investors

2018-04-27 seekingalpha
In June 2017, EQT Corporation announced it would acquire Rice Energy which left the fate of Rice Midstream Partners undetermined. (10-0)

[Press] Shale Gas Hydraulic Fracturing Market will Exhibit a Steady 9.8% CAGR through 2027

2018-04-13 oilvoice
Future Market Insights assesses the shale gas hydraulic fracturing market in the U.S, Canada, and China in its newly published report titled, “Shale Gas Hydraulic Fracturing Market: Canada, US, and China Industry Analysis 2012–2016 and Opportunity Assessment 2017–2027.” According to the report, the US market production value is anticipated to expand from 18,059 BCF (2017) at a 9.8% CAGR, Canadian market's production volume of 213. (79-0)

CUSIP: 762760106